전북대학교산학협력단;INDUSTRIAL COOPERATION FOUNDATION CHONBUK NATIONAL UNIVERSITY
发明人:
JEONG, Hwan Jeong,정환정
申请号：
KRKR2016/005453
公开号：
WO2016/190642A1
申请日:
2016.05.23
申请国别(地区):
KR
年份:
2016
代理人:
摘要：
The present invention relates to: a pharmaceutical composition for preventing or treating ischemic diseases, containing liposomes in which vascular endothelial growth factor (VEGF)-derived peptides are supported； a method for treating ischemic diseases, comprising the step of administering the pharmaceutical composition to an individual suspected of having an ischemic disease； a use of the liposomes； and a kit for evaluating, using the liposomes, the amount of liposomes, in which VEGF-derived peptides are supported, delivered to ischemic lesions and of support materials released and absorbed. The composition, of the present invention, for preventing or treating ischemic diseases, containing liposomes in which VEGF-derived peptides are supported, the liposomes having an average particle size of 90 to 110 nm and a particle distribution of 50 to 200 nm and being surface-modified with polyethylene glycol, is capable of significantly increasing the absorption of VEGF compared with treatment using solely VEGF, thereby effectively treating ischemic diseases such as myocardial infarction, middle cerebral artery stenosis, lower limb ischemia, and cerebral infarction. In addition, the kit provided in the present invention can be useful in evaluating the amount of liposomes, in which VEGF-derived peptides are supported, delivered to ischemic lesions and of support materials released and absorbed, in a treatment step for a patient with ischemic diseases.La présente invention concerne : une composition pharmaceutique pour prévenir ou traiter des maladies ischémiques, contenant des liposomes dans lesquels des peptides dérivés du facteur de croissance endothéliale vasculaire (VEGF) sont supportés ； un procédé pour traiter des maladies ischémiques, comprenant l'étape consistant à administrer la composition pharmaceutique à un individu suspecté d'avoir une maladie ischémique ； une utilisation des liposomes ； et un kit pour évaluer, à l'aide des liposomes, la quantité de liposomes, d
